A phase I/II study of bexarotene in combination with ZD 1839 (IRESSA) in the third line treatment of non-small cell lung cancer (NSCLC).

Trial Profile

A phase I/II study of bexarotene in combination with ZD 1839 (IRESSA) in the third line treatment of non-small cell lung cancer (NSCLC).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 May 2010

At a glance

  • Drugs Bexarotene; Gefitinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 17 Dec 2009 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
    • 07 Oct 2008 Trial identifier 80031 added as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top